selexipag   Click here for help

GtoPdb Ligand ID: 7552

Synonyms: ACT-293987 | NS-304 | Uptravi®
Approved drug
selexipag is an approved drug (FDA (2015), EMA (2016))
Compound class: Synthetic organic
Comment: Selexipag represents a first-in-class selective, long-acting, oral prostacyclin IP receptor agonist. This compound is a prodrug, with the active molecule being MRE-269.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 13
Topological polar surface area 109.87
Molecular weight 496.21
XLogP 4.69
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(NS(=O)(=O)C)COCCCCN(c1cnc(c(n1)c1ccccc1)c1ccccc1)C(C)C
Isomeric SMILES O=C(NS(=O)(=O)C)COCCCCN(c1cnc(c(n1)c1ccccc1)c1ccccc1)C(C)C
InChI InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)
InChI Key QXWZQTURMXZVHJ-UHFFFAOYSA-N
Bioactivity Comments
ADP-induced aggregation of platelets is an in vitro tool used as a surrogate for PGI2 receptor activation.
Selexipag inhibits aggregation of human platelets with an IC50 of 6400nM [1], whereas MRE-269 (the active metabolite) has a much lower IC50 of 200nM [1].
Selectivity at GPCRs
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IP receptor Hs Agonist Agonist 6.6 pKi - 2
pKi 6.6 (Ki 2.6x10-7 M) [2]
IP receptor Rn Agonist Agonist 5.7 pKi - 2
pKi 5.7 (Ki 2.1x10-6 M) [2]